FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4252921710> ?p ?o ?g. }

• W4252921710 endingPage "352.e5" @default.
• W4252921710 startingPage "352" @default.
• W4252921710 abstract "Back to table of contents Previous article Next article LETTERFull AccessAripiprazole in the Treatment of Olanzapine-Resistant Psychotic and Motor Symptoms of Huntington’s DiseasePanagiotis Oulis M.D., Ph.D.Iraklis Mourikis M.D.George Konstantakopoulos M.D.,Sokratis G. Papageorgiou M.D.,Anastasios V. Kouzoupis M.D.,Panagiotis Oulis M.D., Ph.D.Search for more papers by this authorIraklis Mourikis M.D.Search for more papers by this authorGeorge Konstantakopoulos M.D.Search for more papers by this author,Sokratis G. Papageorgiou M.D.Search for more papers by this author,Anastasios V. Kouzoupis M.D.Search for more papers by this author,Published Online:1 Jul 2010https://doi.org/10.1176/jnp.2010.22.3.352.e4AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail To the Editor: Huntington’s disease is an inheritable neurodegenerative disorder with motor and cognitive manifestations, including psychotic ones. Dopamine antagonists such as classical antipsychotics are indicated for the symptomatic treatment of psychosis and chorea in patients with Huntington’s disease. However, they carry the heightened risk of worsening patients’ extrapyramidal symptoms. The same holds, to a lesser extent, for several second-generation antipsychotics. In the following we report on the case of a patient with Huntington’s disease psychosis resistant to olanzapine which moreover worsened his motor, especially extrapyramidal, symptoms, successfully treated with aripiprazole. Case ReportWe present the case of a 47-year-old man with genetically confirmed Huntington’s disease since the age of 43 and delusional explanation of his motor symptoms. More precisely, the patient became convinced that his choreiform movements were caused by the air-conditioner of a café in his neighborhood, and accordingly he declined all proposals for medical care and treatment. He was brought to our attention by his relatives after the last of a series of severe altercations with the café’s owner. He scored 33 on the Positive and Negative Syndrome Scale subscale for positive symptoms (PANSS-P), 21 on the Parkinson and 12 on the Chorea items of the Unified Huntington’s Disease Rating Scale (UHDRS) respectively, and 26 on the Mini-Mental State Examination (MMSE). He was prescribed olanzapine up to 20 mg/day. However, 6 weeks later his delusion proved refractory whereas his motor symptoms worsened (PANSS-P score=25, UHDRS-Parkinson=24, UHDRS-Chorea=16). At that moment, we substituted aripiprazole at 15 mg/day for olanzapine. On his third appointment 1 month later, his delusion had subsided almost completely with a substantial improvement of his motor symptoms as well (PANSS-P=11, UHDRS-Parkinson=20, UHDRS-Chorea=8) whereas his MMSE score remained unchanged. His amelioration was fully preserved until his last follow-up appointment 3 months later.Discussion The clinical manifestations of Huntington’s disease are mediated by the degeneration and apoptosis of striatal neurons. In turn, the latter arises from the expanded huntingtin protein and both glutamatergic input from the cortex and dopaminergic input from subcortical areas. 1 This process of striatal neural degeneration can be reversed by dopamine receptor antagonists. 2 Owing to its recently further elucidated unique mode of action as a functionally selective D 2 ligand, aripiprazole could block excessive mesolimbic dopaminergic neurotransmission involved in the pathophysiology of positive psychotic symptoms without affecting adversely nigrostriatal dopaminergic transmission involved in the pathophysiology of extrapyramidal symptoms. 3 Of note, a recent small study of aripiprazole in Huntington’s disease without psychosis attests to its potential to ameliorate both chorea and parkinsonism without worsening patients’ cognitive symptoms. 4 Moreover, another recent case report suggested that aripiprazole could ameliorate both psychotic and choreiform symptoms of Huntington’s disease in an antipsychotic-naive patient. 5Although anecdotal and thus in need of careful replication in controlled studies of large patient samples, our findings suggest that aripiprazole might be efficacious and comparable to other antipsychotics and a safer option in the treatment of both psychotic and motor symptoms in Huntington’s disease.Athens University Medical School, First Department of Psychiatry, Eginition Hospital, Athens, GreeceAthens University Medical School, Department of Neurology, Eginition Hospital, Athens, GreeceAthens University Medical School, First Department of Psychiatry, Eginition Hospital, AthensReferences1. Paoletti P, Vila I, Rifé M, et al: Dopaminergic and glutamatergic signaling crosstalk in Huntington’s disease neurodegeneration: the role of p25/cyclin-dependent kinase 5. J Neurosci 2008; 28:1090–1101Google Scholar2. Charvin D, Vanhoutte P, Pagès C, et al: Unraveling a role for dopamine in Huntington’s disease: the dual role of reactive oxygen species and D receptor stimulation. Proc Natl Acad Sci U S A 2005; 102:12218–12223Google Scholar3. Han M, Huang XF, Deng C: Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects. Int J Neuropharmacol 2009; 10:1–12Google Scholar4. Brusa L, Orlacchio A, Moscella V, et al: Treatment of the symptoms of Huntington’s disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord 2009; 24:126–129Google Scholar5. Lin WC, Chou Y-H: Aripiprazole effects on psychosis and chorea in a patient with Huntington’s disease. Am J Psychiatry 2008; 165:1207–1208Google Scholar FiguresReferencesCited byDetailsCited ByState-of-the-art pharmacological approaches to reduce chorea in Huntington’s disease8 February 2021 | Expert Opinion on Pharmacotherapy, Vol. 22, No. 8Frontiers in Neurology, Vol. 10, Vol. 144General Hospital Psychiatry, Vol. 36, No. 3Expert Opinion on Pharmacotherapy, Vol. 15, No. 11Managing chorea in Huntington’s diseaseNeurodegenerative Disease Management, Vol. 1, No. 4 Volume 22Issue 3 Summer, 2010Pages 352.e4-352.e5 Metrics PDF download History Published online 1 July 2010 Published in print 1 July 2010" @default.
• W4252921710 created "2022-05-12" @default.
• W4252921710 creator A5065825062 @default.
• W4252921710 creator A5069068590 @default.
• W4252921710 creator A5071668466 @default.
• W4252921710 creator A5074555754 @default.
• W4252921710 creator A5076154762 @default.
• W4252921710 date "2010-08-01" @default.
• W4252921710 modified "2023-09-30" @default.
• W4252921710 title "Aripiprazole in the Treatment of Olanzapine-Resistant Psychotic and Motor Symptoms of Huntington's Disease" @default.
• W4252921710 doi "https://doi.org/10.1176/appi.neuropsych.22.3.352-c.e4" @default.
• W4252921710 hasPublicationYear "2010" @default.
• W4252921710 type Work @default.
• W4252921710 citedByCount "3" @default.
• W4252921710 countsByYear W42529217102014 @default.
• W4252921710 crossrefType "journal-article" @default.
• W4252921710 hasAuthorship W4252921710A5065825062 @default.
• W4252921710 hasAuthorship W4252921710A5069068590 @default.
• W4252921710 hasAuthorship W4252921710A5071668466 @default.
• W4252921710 hasAuthorship W4252921710A5074555754 @default.
• W4252921710 hasAuthorship W4252921710A5076154762 @default.
• W4252921710 hasConcept C118552586 @default.
• W4252921710 hasConcept C126322002 @default.
• W4252921710 hasConcept C15744967 @default.
• W4252921710 hasConcept C187212893 @default.
• W4252921710 hasConcept C2776412080 @default.
• W4252921710 hasConcept C2776619155 @default.
• W4252921710 hasConcept C2778868616 @default.
• W4252921710 hasConcept C2779134260 @default.
• W4252921710 hasConcept C2779727114 @default.
• W4252921710 hasConcept C2780211496 @default.
• W4252921710 hasConcept C2780647506 @default.
• W4252921710 hasConcept C71924100 @default.
• W4252921710 hasConceptScore W4252921710C118552586 @default.
• W4252921710 hasConceptScore W4252921710C126322002 @default.
• W4252921710 hasConceptScore W4252921710C15744967 @default.
• W4252921710 hasConceptScore W4252921710C187212893 @default.
• W4252921710 hasConceptScore W4252921710C2776412080 @default.
• W4252921710 hasConceptScore W4252921710C2776619155 @default.
• W4252921710 hasConceptScore W4252921710C2778868616 @default.
• W4252921710 hasConceptScore W4252921710C2779134260 @default.
• W4252921710 hasConceptScore W4252921710C2779727114 @default.
• W4252921710 hasConceptScore W4252921710C2780211496 @default.
• W4252921710 hasConceptScore W4252921710C2780647506 @default.
• W4252921710 hasConceptScore W4252921710C71924100 @default.
• W4252921710 hasIssue "3" @default.
• W4252921710 hasLocation W42529217101 @default.
• W4252921710 hasOpenAccess W4252921710 @default.
• W4252921710 hasPrimaryLocation W42529217101 @default.
• W4252921710 hasRelatedWork W1993202685 @default.
• W4252921710 hasRelatedWork W2046511192 @default.
• W4252921710 hasRelatedWork W2050132903 @default.
• W4252921710 hasRelatedWork W2052841385 @default.
• W4252921710 hasRelatedWork W2134794586 @default.
• W4252921710 hasRelatedWork W2315498149 @default.
• W4252921710 hasRelatedWork W2391989814 @default.
• W4252921710 hasRelatedWork W3032738626 @default.
• W4252921710 hasRelatedWork W3190528870 @default.
• W4252921710 hasRelatedWork W2493645882 @default.
• W4252921710 hasVolume "22" @default.
• W4252921710 isParatext "false" @default.
• W4252921710 isRetracted "false" @default.
• W4252921710 workType "article" @default.